Grünenthal appoints Oscar Ferenczi to lead its Latin America business

Aachen (ots) -

Oscar Ferenczi, former Region Head of Sandoz Latin America, takes
over responsibility for Grünenthal's Strategic Business Unit (SBU)
LATAM.

Today, the Grünenthal Group announced the appointment of Oscar
Ferenczi to Executive Vice President for the SBU Grünenthal Latin
America with immediate effect. In his responsibility he will also
take over the task of General Manager Grünenthal S.A. Panama, the
regional head office of the company in Latin America, as well as
General Manger Grünenthal Latin America, Miami. As a member of the
Group Operating Committee of the pain specialist headquartered in
Aachen (Germany), Oscar Ferenczi will be based in Miami, Florida, and
will report directly to Grünenthal Group Chief Executive Officer,
Harald F. Stock, Ph.D.

"Strengthening our businesses in Latin America is one of our core
strategic objectives as we are aiming to generate 40 percent of
Grünenthal's commercial business from the region in 2015. I am glad
that Oscar has decided to lead the Group's Strategic Business Unit
with its ambitious, dedicated, and passionate people. He joins
Grünenthal with a successful track record in general management,
marketing, sales and finance in both the generics and patented
segments of the pharmaceutical industry", commented Harald F. Stock,
Ph.D., CEO of the Grünenthal Group.

Oscar Ferenczi, Executive Vice President SBU LATAM, is looking
forward to his new position at Grünenthal: "I am excited about
joining Grünenthal and the opportunity to lead the team into a
driving force in Latin America. Given the potential of the region and
the opportunities that exist, I see Grünenthal's strategic plans as
the basis for its overall success and positioning in the region."

Excellent position for further growth - both organic and external
In Latin America, Grünenthal is further strengthening the business in
these fast-growth emerging markets with selected acquisitions and
licensing deals. Following the successful acquisition and integration
of the Brazilian company Selfarma in 2011, Grünenthal announced in
June 2012 an exclusive agreement with US-based Horizon Pharma for the
commercialization of DUEXIS® in Latin America. The company's current
leading market position in Latin America is mainly based on a strong
portfolio in pain, Grünenthal's global core competence along with
strong regional products.

More information about Grünenthal: www.grunenthal.com

Additional information for editorial offices: Oscar Ferenczi's CV
can be downloaded on our website: http://ots.de/gUNiG

Contact:
Frank Schönrock, Vice President Corporate Affairs
Tel.: +49 241 569-1568, Fax: +49 241 569-3539,
frank.schoenrock@grunenthal.com

Grünenthal GmbH, 52099 Aachen,
Deutschland, www.grunenthal.com